ACER - オペクサ・セラピュ―ティクス （Acer Therapeutics Inc.）

Now’s a great time to start considering which micro-cap stocks to buy. Generally, micro-caps are stocks with a market capitalization of less than $300 million. With a cap like that, the company doesn’t have a ton of resources – which means that it could be forced to go into debt in order to grow, or it may not have enough wiggle room to withstand extended losses or mismanagement. It’s not uncommon to see some of the most interesting micro-cap stocks to buy trading on over-the-counter indices rather than the New York Stock Exchange or the Nasdaq. If that’s the case with a company you’re considering, just keep in mind that OTC markets or pink sheets don’t have the same listing standards as the major indices. That means that as an investor you will likely have less information to go on as you make your decision to buy, sell or hold. I’m using my Portfolio Grader tool to help us with an evaluation of some high-risk micro-cap stocks to buy. These names all have an “A” or “B” grade in the Portfolio Grader based on their earnings history, performance, momentum and other factors.

During the last session, Acer Therapeutics Inc. (NASDAQ:ACER)’s traded shares were 0.48 million, with the beta value of the company hitting 0.69. At the end of the trading day, the stock’s price was $2.41, reflecting an intraday gain of 0.84% or $0.02. The 52-week high for the ACER share is $4.56, that puts it down … After A -20.98% Drop In The Last Week, Does Acer Therapeutics Inc. (NASDAQ: ACER) Still Make Sense To Buy? Read More »

ZyVersa Therapeutics (ZVSA) +47%. Jasper Therapeutics JSPR +41%. Biora Therapeutics (BIOR) -15%. Acer Therapeutics (ACER) -10%.

Acer Therapeutics (ACER) is trading ~5% higher after the company began two Phase 2 investigator-sponsored trials evaluating ACER-801 (osanetant) in men with adenocarcinoma of…

Acer Therapeutics''s (NASDAQ: ACER ) short percent of float has risen 716.36% since its last report. The company recently reported that it has 657 thousand shares sold short , which is 4.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.8 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com

Acer Therapeutics Inc. (NASDAQ:ACER) marked $1.51 per share on Tuesday, up from a previous closing price of $1.44. While Acer Therapeutics Inc. has overperformed by 4.86%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACER fell by -38.37%, with highs and lows ranging from $3.77 to […]

Acer Therapeutics press release (ACER): Q2 GAAP EPS of -$0.17 beats by $0.42.Cash and cash equivalents were $14.5 million

NEWTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.

In last trading session, Acer Therapeutics Inc. (NASDAQ:ACER) saw 0.32 million shares changing hands with its beta currently measuring 1.48. Company’s recent per share price level of $1.47 trading at -$0.01 or -0.67% at ring of the bell on the day assigns it a market valuation of $25.93M. That closing price of ACER’s stock is … Acer Therapeutics Inc. (NASDAQ:ACER) Shares Are Up 21.09% From The Lows, But Can They Stay Up? Read More »

The European Commission granted orphan medicinal product designation to Acer Therapeutics (ACER) and Relief Therapeutics'' (RLFTF) (RLFTY) ACER-001 (sodium phenylbutyrate) to treat…

Acer Therapeutics (NASDAQ:ACER) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Profitability This table compares Acer Therapeutics and CV Sciences net margins, return on equity and []

Phase 2a trial initiation expected in Q1 2022

Acer Therapeutics (NASDAQ:ACER) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The companys product pipeline consists of []

Equities analysts expect that Acer Therapeutics Inc. (NASDAQ:ACER) will announce earnings of ($0.24) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Acer Therapeutics earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.22). Acer Therapeutics posted earnings of ($0.50) per share during the same []